Does an off-label two-dose RotaTeq vaccine schedule translate into a higher incidence of rotavirus hospital admissions compared to the approved three-dose RotaTeq schedule? A Canadian immunization research network study.

Saved in:
Bibliographic Details
Title: Does an off-label two-dose RotaTeq vaccine schedule translate into a higher incidence of rotavirus hospital admissions compared to the approved three-dose RotaTeq schedule? A Canadian immunization research network study.
Authors: Fortin É; Département de médecine sociale et préventive, Faculté de Médicine, Université Laval, Quebec, Quebec, Canada; Biological Risks Departement, Institut national de santé publique du Québec (INSPQ), Quebec, Quebec, Canada; Department of Microbiology, Infectious Diseases, and Immunology, Faculty of Medicine, University of Montreal, Quebec, Canada., Miron É; Département de médecine sociale et préventive, Faculté de Médicine, Université Laval, Quebec, Quebec, Canada., Grewal R; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada., Wilson SE; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada; Public Health Ontario, Toronto, Ontario, Canada; Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada., Janjua NZ; UBC Centre for Disease Control, University of British Columbia, Vancouver, BC, Canada; School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Quach C; Departments of Microbiology, Infectious Diseases, and Immunology & of Pediatrics, Université de Montréal and Clinical Department of Laboratory Medicine, CHU Sainte-Justine, Montreal, Quebec, Canada., Sadarangani M; Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada., Kiely M; Département de médecine sociale et préventive, Faculté de Médicine, Université Laval, Quebec, Quebec, Canada; CHU de Québec Research Centre - Université Laval, Quebec, Quebec, Canada., Naveed Z; UBC Centre for Disease Control, University of British Columbia, Vancouver, BC, Canada., Naus M; School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., MacDonald SE; Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada., Swayze S; Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada., Brousseau N; Département de médecine sociale et préventive, Faculté de Médicine, Université Laval, Quebec, Quebec, Canada; Biological Risks Departement, Institut national de santé publique du Québec (INSPQ), Quebec, Quebec, Canada; CHU de Québec Research Centre - Université Laval, Quebec, Quebec, Canada. Electronic address: nicholas.brousseau@inspq.qc.ca.
Source: Vaccine [Vaccine] 2026 Jun 11; Vol. 83, pp. 128628. Date of Electronic Publication: 2026 May 02.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2026.128628